Methylenetetrahydrofolate reductase polymorphisms and the risk of gestational hypertension

Sonia Hernández-Díaz, Xiao F. Wu, Catherine Hayes, Martha M. Werler, Tara Devi S Ashok, Rachel Badovinac, Karl T. Kelsey, Allen A. Mitchell

Research output: Contribution to journalArticle

Abstract

Background: Evidence on the association of 5,10 methylentetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms in women with gestational hypertension is inconsistent. It is also unknown whether the fetal genotype is relevant, or whether folic acid supplementation modifies this association. Methods: The study population was composed of U.S. and Canadian white women with nonmalformed infants participating in the Slone Epidemiology Center Birth Defects Study between 1993 and 2000. Women were interviewed within 6 months after delivery regarding multivitamin use in pregnancy and the occurrence of gestational hypertension, among other factors. DNA was extracted from cheek swabs and gene alleles determined by restriction fragment length polymorphism analysis. We compared the prevalence of the 677TT/CT and 1298CC/AC genotypes between cases with gestational hypertension (54 mothers and their 51 offspring) and controls (100 mothers and their 99 offspring). We also estimated odds ratios (ORs) and 95% confidence intervals (CIs) using conditional logistic regression to control for geographic region and calendar year. Results: The T allele was present in 69% of women with gestational hypertension versus 57% of control women (compared with 677CC, OR = 1.9; 95% CI = 0.9-4.0). The offspring of case and control women had a 677TT/CT genotype prevalence of 68% and 47%, respectively (2.4; 1.1-5.0). Among women supplemented with folic acid during the first 5 months of pregnancy, the ORs for maternal and fetal 677TT/CT genotypes were 0.9 (0.3-2.5) and 2.1 (0.7-6.0), respectively. Neither maternal nor fetal 1298CC/AC genotypes were associated with an increased risk of gestational hypertension. Conclusion: Maternal and fetal MTHFR C677T polymorphism may be associated with a moderately increased risk of gestational hypertension, and there is a suggestion that this association may be diminished among women receiving folate supplementation during pregnancy.

Original languageEnglish (US)
Pages (from-to)628-634
Number of pages7
JournalEpidemiology
Volume16
Issue number5
DOIs
StatePublished - Sep 2005

Fingerprint

Methylenetetrahydrofolate Reductase (NADPH2)
Pregnancy Induced Hypertension
Genotype
Mothers
Folic Acid
Odds Ratio
Pregnancy
Oxidoreductases
Alleles
Confidence Intervals
Cheek
Restriction Fragment Length Polymorphisms
Epidemiology
Logistic Models
DNA

ASJC Scopus subject areas

  • Epidemiology

Cite this

Hernández-Díaz, S., Wu, X. F., Hayes, C., Werler, M. M., Ashok, T. D. S., Badovinac, R., ... Mitchell, A. A. (2005). Methylenetetrahydrofolate reductase polymorphisms and the risk of gestational hypertension. Epidemiology, 16(5), 628-634. https://doi.org/10.1097/01.ede.0000172132.13513.e0

Methylenetetrahydrofolate reductase polymorphisms and the risk of gestational hypertension. / Hernández-Díaz, Sonia; Wu, Xiao F.; Hayes, Catherine; Werler, Martha M.; Ashok, Tara Devi S; Badovinac, Rachel; Kelsey, Karl T.; Mitchell, Allen A.

In: Epidemiology, Vol. 16, No. 5, 09.2005, p. 628-634.

Research output: Contribution to journalArticle

Hernández-Díaz, S, Wu, XF, Hayes, C, Werler, MM, Ashok, TDS, Badovinac, R, Kelsey, KT & Mitchell, AA 2005, 'Methylenetetrahydrofolate reductase polymorphisms and the risk of gestational hypertension', Epidemiology, vol. 16, no. 5, pp. 628-634. https://doi.org/10.1097/01.ede.0000172132.13513.e0
Hernández-Díaz S, Wu XF, Hayes C, Werler MM, Ashok TDS, Badovinac R et al. Methylenetetrahydrofolate reductase polymorphisms and the risk of gestational hypertension. Epidemiology. 2005 Sep;16(5):628-634. https://doi.org/10.1097/01.ede.0000172132.13513.e0
Hernández-Díaz, Sonia ; Wu, Xiao F. ; Hayes, Catherine ; Werler, Martha M. ; Ashok, Tara Devi S ; Badovinac, Rachel ; Kelsey, Karl T. ; Mitchell, Allen A. / Methylenetetrahydrofolate reductase polymorphisms and the risk of gestational hypertension. In: Epidemiology. 2005 ; Vol. 16, No. 5. pp. 628-634.
@article{0d44957e3e1c48bb8f81f4c50266bff2,
title = "Methylenetetrahydrofolate reductase polymorphisms and the risk of gestational hypertension",
abstract = "Background: Evidence on the association of 5,10 methylentetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms in women with gestational hypertension is inconsistent. It is also unknown whether the fetal genotype is relevant, or whether folic acid supplementation modifies this association. Methods: The study population was composed of U.S. and Canadian white women with nonmalformed infants participating in the Slone Epidemiology Center Birth Defects Study between 1993 and 2000. Women were interviewed within 6 months after delivery regarding multivitamin use in pregnancy and the occurrence of gestational hypertension, among other factors. DNA was extracted from cheek swabs and gene alleles determined by restriction fragment length polymorphism analysis. We compared the prevalence of the 677TT/CT and 1298CC/AC genotypes between cases with gestational hypertension (54 mothers and their 51 offspring) and controls (100 mothers and their 99 offspring). We also estimated odds ratios (ORs) and 95{\%} confidence intervals (CIs) using conditional logistic regression to control for geographic region and calendar year. Results: The T allele was present in 69{\%} of women with gestational hypertension versus 57{\%} of control women (compared with 677CC, OR = 1.9; 95{\%} CI = 0.9-4.0). The offspring of case and control women had a 677TT/CT genotype prevalence of 68{\%} and 47{\%}, respectively (2.4; 1.1-5.0). Among women supplemented with folic acid during the first 5 months of pregnancy, the ORs for maternal and fetal 677TT/CT genotypes were 0.9 (0.3-2.5) and 2.1 (0.7-6.0), respectively. Neither maternal nor fetal 1298CC/AC genotypes were associated with an increased risk of gestational hypertension. Conclusion: Maternal and fetal MTHFR C677T polymorphism may be associated with a moderately increased risk of gestational hypertension, and there is a suggestion that this association may be diminished among women receiving folate supplementation during pregnancy.",
author = "Sonia Hern{\'a}ndez-D{\'i}az and Wu, {Xiao F.} and Catherine Hayes and Werler, {Martha M.} and Ashok, {Tara Devi S} and Rachel Badovinac and Kelsey, {Karl T.} and Mitchell, {Allen A.}",
year = "2005",
month = "9",
doi = "10.1097/01.ede.0000172132.13513.e0",
language = "English (US)",
volume = "16",
pages = "628--634",
journal = "Epidemiology",
issn = "1044-3983",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Methylenetetrahydrofolate reductase polymorphisms and the risk of gestational hypertension

AU - Hernández-Díaz, Sonia

AU - Wu, Xiao F.

AU - Hayes, Catherine

AU - Werler, Martha M.

AU - Ashok, Tara Devi S

AU - Badovinac, Rachel

AU - Kelsey, Karl T.

AU - Mitchell, Allen A.

PY - 2005/9

Y1 - 2005/9

N2 - Background: Evidence on the association of 5,10 methylentetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms in women with gestational hypertension is inconsistent. It is also unknown whether the fetal genotype is relevant, or whether folic acid supplementation modifies this association. Methods: The study population was composed of U.S. and Canadian white women with nonmalformed infants participating in the Slone Epidemiology Center Birth Defects Study between 1993 and 2000. Women were interviewed within 6 months after delivery regarding multivitamin use in pregnancy and the occurrence of gestational hypertension, among other factors. DNA was extracted from cheek swabs and gene alleles determined by restriction fragment length polymorphism analysis. We compared the prevalence of the 677TT/CT and 1298CC/AC genotypes between cases with gestational hypertension (54 mothers and their 51 offspring) and controls (100 mothers and their 99 offspring). We also estimated odds ratios (ORs) and 95% confidence intervals (CIs) using conditional logistic regression to control for geographic region and calendar year. Results: The T allele was present in 69% of women with gestational hypertension versus 57% of control women (compared with 677CC, OR = 1.9; 95% CI = 0.9-4.0). The offspring of case and control women had a 677TT/CT genotype prevalence of 68% and 47%, respectively (2.4; 1.1-5.0). Among women supplemented with folic acid during the first 5 months of pregnancy, the ORs for maternal and fetal 677TT/CT genotypes were 0.9 (0.3-2.5) and 2.1 (0.7-6.0), respectively. Neither maternal nor fetal 1298CC/AC genotypes were associated with an increased risk of gestational hypertension. Conclusion: Maternal and fetal MTHFR C677T polymorphism may be associated with a moderately increased risk of gestational hypertension, and there is a suggestion that this association may be diminished among women receiving folate supplementation during pregnancy.

AB - Background: Evidence on the association of 5,10 methylentetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms in women with gestational hypertension is inconsistent. It is also unknown whether the fetal genotype is relevant, or whether folic acid supplementation modifies this association. Methods: The study population was composed of U.S. and Canadian white women with nonmalformed infants participating in the Slone Epidemiology Center Birth Defects Study between 1993 and 2000. Women were interviewed within 6 months after delivery regarding multivitamin use in pregnancy and the occurrence of gestational hypertension, among other factors. DNA was extracted from cheek swabs and gene alleles determined by restriction fragment length polymorphism analysis. We compared the prevalence of the 677TT/CT and 1298CC/AC genotypes between cases with gestational hypertension (54 mothers and their 51 offspring) and controls (100 mothers and their 99 offspring). We also estimated odds ratios (ORs) and 95% confidence intervals (CIs) using conditional logistic regression to control for geographic region and calendar year. Results: The T allele was present in 69% of women with gestational hypertension versus 57% of control women (compared with 677CC, OR = 1.9; 95% CI = 0.9-4.0). The offspring of case and control women had a 677TT/CT genotype prevalence of 68% and 47%, respectively (2.4; 1.1-5.0). Among women supplemented with folic acid during the first 5 months of pregnancy, the ORs for maternal and fetal 677TT/CT genotypes were 0.9 (0.3-2.5) and 2.1 (0.7-6.0), respectively. Neither maternal nor fetal 1298CC/AC genotypes were associated with an increased risk of gestational hypertension. Conclusion: Maternal and fetal MTHFR C677T polymorphism may be associated with a moderately increased risk of gestational hypertension, and there is a suggestion that this association may be diminished among women receiving folate supplementation during pregnancy.

UR - http://www.scopus.com/inward/record.url?scp=24144447646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24144447646&partnerID=8YFLogxK

U2 - 10.1097/01.ede.0000172132.13513.e0

DO - 10.1097/01.ede.0000172132.13513.e0

M3 - Article

VL - 16

SP - 628

EP - 634

JO - Epidemiology

JF - Epidemiology

SN - 1044-3983

IS - 5

ER -